Efficacy and safety of tazemetostat in patients with R/R FL

Results from the phase II study (NCT01897571) of tazemetostat, a selective oral EZH2 inhibitor, in patients with relapsed/refractory (R/R) follicular lymphoma (FL) show encouraging clinical efficacy and safety.

This study evaluated the safety and efficacy of tazemetostat in patients with R/R FL with mutant or wild-type EZH2 FL. Tazemetostat was tolerable, with a low prevalence of treatment-related adverse events, and demonstrated good clinical efficacy even in high-risk subgroups. Results from this trial have been recently reported in Lancet Oncology.

Key safety and efficacy results were presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition; read more here. Based on the phase II trial results, tazemetostat has been granted supplemental new drug application approval by the U.S. Food and Drug Administration (FDA) for the treatment of R/R FL with EZH2 mutation and R/R FL with no alternative treatment options.